Development and validation of a nomogram based on tumor margin irregularity and alpha-fetoprotein for predicting microvascular invasion in hepatocellular carcinoma - Takeaways - MDSpire

Development and validation of a nomogram based on tumor margin irregularity and alpha-fetoprotein for predicting microvascular invasion in hepatocellular carcinoma

  • By

  • Xiang Huang

  • Xiaofeng Chen

  • Xiangguang Chen

  • Ruibin Huang

  • Zhuozhi Dai

  • Ruyao Zhuang

  • Zhiqi Yang

  • June 26, 2026

  • 0 min

Share

  • 1

    A nomogram was developed to predict microvascular invasion (MVI) in hepatocellular carcinoma (HCC) using tumor margin irregularity and alpha-fetoprotein (AFP) levels.

  • 2

    The study included 487 patients in the training cohort and 256 patients in the validation cohort, all with pathologically confirmed HCC.

  • 3

    Independent predictors of MVI identified were irregular tumor margins (adjusted OR = 5.275) and AFP positivity (adjusted OR = 3.297).

  • 4

    The final nomogram achieved AUCs of 0.740 in the training cohort and 0.781 in the validation cohort, indicating fair-to-acceptable discrimination.

  • 5

    The study suggests that the nomogram may assist in preoperative MVI risk stratification for patients with HCC, pending further validation.

Original Source(s)

Development and validation of a nomogram based on tumor margin irregularity and alpha-fetoprotein for predicting microvascular invasion in hepatocellular carcinoma

  • by Xiang Huang, Xiaofeng Chen, Xiangguang Chen, Ruibin Huang, Zhuozhi Dai, Ruyao Zhuang, Zhiqi Yang

  • June 26, 2026

Related Content

A systematic review and meta-analysis of the effects of walking training on cardiorespiratory fitness in cancer patients

Troponin for surveillance of immune checkpoint inhibitor–associated myocarditis and post-therapy cardiovascular risk stratification: a systematic review and meta-analysis

ESMO Breast Cancer 2026 Highlights Panel Discussion

Harold Burstein, MD, PhD; Sara Tolaney, MD, MPH; Erica L. Mayer, MD, MPH; Nancy Lin, MD; and Ana C. Garrido-Castro, MD discuss important breast cancer research presented at the 2026 ESMO Breast Cancer Congress.

  • June 26, 2026

  • 1 min